MedTrace Logo

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

NCT00652223 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2008-04-09

No results posted yet for this study

Summary

The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.

Conditions

  • Perennial Allergic Rhinoconjunctivitis
  • Allergic Asthma

Interventions

BIOLOGICAL

CYT005-AllQbG10

Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT

Sponsors & Collaborators

  • Cytos Biotechnology AG

    lead INDUSTRY

Principal Investigators

  • Philipp Mueller, MD · Cytos Biotechnology AG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2005-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652223 on ClinicalTrials.gov